Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 9 | 2025 | 81 | 3.510 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2021 | 187 | 2.300 |
Why?
|
| Immunotoxins | 3 | 2023 | 13 | 1.090 |
Why?
|
| MicroRNAs | 4 | 2017 | 501 | 0.930 |
Why?
|
| Interferon Type I | 1 | 2023 | 18 | 0.840 |
Why?
|
| Apoptosis | 7 | 2025 | 1541 | 0.700 |
Why?
|
| Benzofurans | 2 | 2010 | 22 | 0.630 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 31 | 0.530 |
Why?
|
| Vitamin E | 2 | 2008 | 56 | 0.510 |
Why?
|
| Mice, Nude | 7 | 2025 | 403 | 0.500 |
Why?
|
| Cell Line, Tumor | 10 | 2025 | 2598 | 0.450 |
Why?
|
| Replicon | 1 | 2014 | 7 | 0.440 |
Why?
|
| Viral Structural Proteins | 1 | 2014 | 17 | 0.440 |
Why?
|
| Mice | 12 | 2025 | 6490 | 0.440 |
Why?
|
| Dengue Vaccines | 1 | 2014 | 15 | 0.430 |
Why?
|
| Salvia miltiorrhiza | 2 | 2010 | 5 | 0.410 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2010 | 26 | 0.410 |
Why?
|
| Dengue | 1 | 2014 | 100 | 0.390 |
Why?
|
| Cyclooxygenase 2 | 2 | 2011 | 106 | 0.380 |
Why?
|
| Genetic Testing | 1 | 2011 | 90 | 0.330 |
Why?
|
| Animals | 15 | 2025 | 16695 | 0.320 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 145 | 0.320 |
Why?
|
| Pyrazoles | 1 | 2010 | 93 | 0.320 |
Why?
|
| Sulfonamides | 1 | 2010 | 88 | 0.310 |
Why?
|
| Cell Proliferation | 6 | 2025 | 1420 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 209 | 0.290 |
Why?
|
| Ceramides | 1 | 2008 | 43 | 0.280 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 683 | 0.260 |
Why?
|
| Humans | 21 | 2025 | 42163 | 0.260 |
Why?
|
| Cheek | 1 | 2005 | 13 | 0.240 |
Why?
|
| Mouth Neoplasms | 1 | 2005 | 60 | 0.230 |
Why?
|
| Pyrimidinones | 1 | 2025 | 12 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 1068 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2025 | 62 | 0.220 |
Why?
|
| Transfection | 2 | 2017 | 526 | 0.220 |
Why?
|
| Pyridones | 1 | 2025 | 50 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2025 | 339 | 0.210 |
Why?
|
| Congenital Hypothyroidism | 1 | 2024 | 4 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 159 | 0.210 |
Why?
|
| Cricetinae | 3 | 2020 | 241 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 686 | 0.200 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 49 | 0.200 |
Why?
|
| Quinolines | 2 | 2020 | 76 | 0.190 |
Why?
|
| Signal Transduction | 2 | 2023 | 2111 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 185 | 0.170 |
Why?
|
| Vertebrates | 1 | 2020 | 33 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2021 | 136 | 0.160 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 51 | 0.160 |
Why?
|
| Dinoprostone | 2 | 2010 | 69 | 0.160 |
Why?
|
| Doxorubicin | 2 | 2012 | 95 | 0.150 |
Why?
|
| Virus Replication | 1 | 2020 | 318 | 0.140 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 138 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 3 | 2011 | 506 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2009 | 411 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 129 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 61 | 0.130 |
Why?
|
| Male | 6 | 2017 | 22779 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2020 | 548 | 0.130 |
Why?
|
| Tocopherols | 2 | 2008 | 61 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2017 | 69 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 129 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2015 | 75 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 59 | 0.120 |
Why?
|
| Cell Line | 2 | 2020 | 1416 | 0.110 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2015 | 76 | 0.110 |
Why?
|
| HIV-1 | 1 | 2020 | 747 | 0.110 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 68 | 0.110 |
Why?
|
| Neoplasms | 2 | 2015 | 1341 | 0.110 |
Why?
|
| Virus Assembly | 1 | 2014 | 44 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 293 | 0.110 |
Why?
|
| Capsid Proteins | 1 | 2014 | 74 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2014 | 168 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 158 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 979 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2012 | 189 | 0.100 |
Why?
|
| Dengue Virus | 1 | 2014 | 89 | 0.100 |
Why?
|
| Colony-Forming Units Assay | 2 | 2011 | 9 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2015 | 267 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2025 | 933 | 0.090 |
Why?
|
| Loperamide | 1 | 2012 | 1 | 0.090 |
Why?
|
| Gene Expression | 1 | 2015 | 692 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1188 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 52 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1559 | 0.090 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 30 | 0.090 |
Why?
|
| Prostatic Hyperplasia | 1 | 2011 | 32 | 0.090 |
Why?
|
| Prostatectomy | 1 | 2011 | 69 | 0.080 |
Why?
|
| Caspase 3 | 2 | 2008 | 226 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 438 | 0.080 |
Why?
|
| Cell Division | 1 | 2010 | 314 | 0.080 |
Why?
|
| Cell Survival | 2 | 2015 | 934 | 0.080 |
Why?
|
| Mouth Mucosa | 1 | 2009 | 30 | 0.080 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2009 | 19 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 98 | 0.080 |
Why?
|
| Keratinocytes | 1 | 2009 | 67 | 0.070 |
Why?
|
| Caspases | 1 | 2009 | 148 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 134 | 0.070 |
Why?
|
| Caspase 9 | 1 | 2008 | 30 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2012 | 1265 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 1679 | 0.070 |
Why?
|
| Survival Rate | 1 | 2009 | 353 | 0.070 |
Why?
|
| Infrared Rays | 1 | 2008 | 17 | 0.070 |
Why?
|
| Transferrin | 1 | 2008 | 38 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 78 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1139 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 649 | 0.070 |
Why?
|
| Mutation | 2 | 2024 | 1169 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 290 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2009 | 884 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2007 | 151 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 577 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2009 | 1617 | 0.060 |
Why?
|
| Nicotine | 1 | 2007 | 290 | 0.050 |
Why?
|
| Iodide Peroxidase | 1 | 2024 | 35 | 0.050 |
Why?
|
| Autophagy | 1 | 2025 | 136 | 0.050 |
Why?
|
| Radiography | 1 | 2023 | 72 | 0.050 |
Why?
|
| Female | 4 | 2015 | 24018 | 0.050 |
Why?
|
| District of Columbia | 1 | 2022 | 73 | 0.050 |
Why?
|
| Health Services | 1 | 2022 | 62 | 0.050 |
Why?
|
| Furin | 1 | 2020 | 6 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 109 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2020 | 50 | 0.040 |
Why?
|
| Protein Phosphatase 1 | 1 | 2020 | 70 | 0.040 |
Why?
|
| Hela Cells | 1 | 2020 | 370 | 0.040 |
Why?
|
| Mass Screening | 1 | 2024 | 531 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2020 | 196 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 359 | 0.040 |
Why?
|
| Aged | 1 | 2011 | 7982 | 0.040 |
Why?
|
| Proteins | 1 | 2020 | 383 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 680 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 663 | 0.030 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2015 | 9 | 0.030 |
Why?
|
| Diamines | 1 | 2015 | 8 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1554 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 37 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2015 | 26 | 0.030 |
Why?
|
| Middle Aged | 1 | 2011 | 11819 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2015 | 35 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 522 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 249 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 182 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 352 | 0.030 |
Why?
|
| DNA | 1 | 2015 | 594 | 0.020 |
Why?
|
| Rhodamine 123 | 1 | 2012 | 3 | 0.020 |
Why?
|
| Antidiarrheals | 1 | 2012 | 4 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 28 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 860 | 0.020 |
Why?
|
| United States | 1 | 2022 | 5072 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 111 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 81 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2012 | 383 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 348 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 25 | 0.020 |
Why?
|
| Exocytosis | 1 | 2008 | 49 | 0.020 |
Why?
|
| Fluorescence | 1 | 2008 | 113 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2007 | 32 | 0.020 |
Why?
|
| Endocytosis | 1 | 2008 | 117 | 0.020 |
Why?
|
| Necrosis | 1 | 2007 | 54 | 0.020 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2007 | 54 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 151 | 0.020 |
Why?
|
| Smoking | 1 | 2007 | 1019 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 3942 | 0.010 |
Why?
|